The UK government's new 10-year cancer strategy delivering plans to significantly improve cancer survival through earlier diagnosis and faster access to treatment means a commitment to rapidly expanding the use of robotic surgery across the NHS; the ability of devices to integrate into robotic platforms is increasingly important. The target is 75% five-year survival by 20351.
Wes Streeting, Health Secretary, highlighted advances in medical science and technology will “transform the life chances of cancer patients”, with a commitment to rapidly expanding the use of robotic surgery across the NHS.
The DEKA SmartXide Trio is currently the only evidence-based CO2 Laser available for purchase via Supply Chain being used in laser assisted TORS in the UK:
https://link.springer.com/article/10.1007/s10103-026-04801-y
Ensure your next CO2 surgical Laser can assist in delivering the best treatment approach for your cancer patients by preserving clear dissection margins, improved functional outcomes and reduced hospital stay.
FURTHER INFORMATION:
For more information or arrange a SmartXide Trio trial, contact Hannah Laming.
E: HLaming@lynton.co.uk
W: https://lynton.co.uk/surgical/
1 BBC News: https://www.bbc.co.uk/news/articles/cly139el05go
